Clinical Trials at Saint Peter's University Hospital

Open for Enrollment

BREAST

A Study to Examine Reduced Screening Mammography Compliance for Women being Treated at the Breast Center at Saint Peter’s University Hospital


RTOG 1005
A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer


RTOG 0413/NSABP B-39
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer


NSABP B-43
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.


SWOG S0500
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment.


SWOG S1007
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.

MammoSite^®

A Single Site Prospective, Non- randomized Study of the MammoSite^® Radiation Therapy Delivery System (Breast Brachytherapy Applicator) to Evaluate Local Tumor Control, Cosmetic Outcome, and Toxicities.

GASTROINTESTIONAL

Probiotics
Phase II Study of Lactobacillus and Bifidobacterium Supplementation (Theralac®) in Reducing the Severity and Frequency of Cancer Treatment Induced Diarrhea .

GENITOURINARY

SWOG S0931
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

HEAD AND NECK

RTOG 0920
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer.

Lung

ECOG 1505
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (> 4cm) – IIIA Non-Small Cell Lung Cancer (NSCLC).

REGISTRY STUDIES (Non-treatment, observational only)

Connect^™ CLL

The Chronic Lymphocytic Leukemia Disease Registry

Cyberknife

ReCKord^™ CyberKnife^® Registry

CONTACT LIST

Gopal Desai, M.D.
Chairman, Radiation Oncology
Telephone: (732) 745-6690

Alexander Haas, M.D.
Radiation Oncologist
Telephone: (732) 745-6689

Hemangini Shah, M.D.
Radiation Oncologist
Telephone: (732) 745-6691

Scarlett Szymanski
Director of Ambulatory Oncology Services
Telephone (732) 745-6687
Cell: (908) 812-0464

Kathy Covert, APN-BC, MSN, AOCN
Oncology Research Nurse
Telephone: (732) 745-8600 ext. 6163
Beeper: (732) 651-3970

Christopher Buck, MS, RN
Oncology Research Nurse
Telephone: (732) 745-8600 ext. 8295

---

Pediatric Clinical Trials

Non-Treatment/Observational or Biology/Banking Studies

ACCRN07
Protocol for the Enrollment on the Official COG Registry. The Childhood Cancer Research Network (CCRN)


ALTE03N1
Key Adverse Events Following Childhood Cancer


ALTE05N1
Umbrella Long-Term Follow-up Protocol


ANHL04B1
Rare and Cutaneous Non-Hodgkin Lymphoma Registry


ANBL00B1
Neuroblastoma Biology Studies


ABTR01B1
Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors


AHOD04B1
Banking in Hodgkin Disease


AREN03B2
Renal Tumors Classification, Biology and Banking Study


D9902
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol


AALL08B1
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)


AAML08B1
Biology Study of Transient Myeloproliferatie Disorder (TMD) in Children with Down Syndrome (DS)


ACNS02B3
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens

Neuroblastoma Treatment Studies

ANBL0032
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue


ANBL0532
Phase III Randomized Trial of Single vs. Tandem Myeloablative as Consolidation Therapy for High-Risk Neuroblastoma

Medulloblastoma Treatment Studies

ACNS0331
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial


ACNS0332
Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNT Patients

Rhabdomyosarcoma Treatment Studies

ARST0921
A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma


ARST0332
Risk Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)


ARST0531
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC alternating with Vincristin and Irinotecan (VI) for patients with Intermediate-risk Rhabdomyosarcoma (RMS)

Acute Lymphoblastic Leukemia (ALL) Treatment Studies

AALL07P1
A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443 ) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)


AALL0434
Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for children and Young Adults with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (PK Portion Closed)


AALL0631
A Phase III Study of Risk Directed therapy for Infants with ALL: Randomization of Highest Risk Infants to Intensive chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND #76431; NSC#617807


AALL0932
Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia (AML) Treatment Studies

ACCL0933
A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Wilms Tumor Treatment Studies

AREN0532
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor


AREN0533
WILMS Tumor Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumor


AREN0534
Treatment for Pateints with Bilateral Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor

Hepatoblastoma Treatment Studies

AHEP0731
Treatment of Children with All Stages of Hepatoblastoma

PEDIATRIC CONTACT LIST

Dr. Stan Calderwood,
Section Chief, Pediatric Hematology/ Oncology
Children’s Oncology Group Principle Investigator
732-745-6674

Dr. Ionela Iacobas,
Vascular Malformation and Tumor Program Director
Children’s Oncology Group Co-Investigator
732-745-6674

Monique Tabachri,
Clinical Research Associate
Children’s Oncology Group
732-745-6674